Core Viewpoint - Da An Gene (002030.SZ) announced a framework agreement for the acquisition of its controlling stake by Guangzhou Pharmaceutical Group, which will result in Guangzhou Pharmaceutical controlling 26.63% of Da An Gene's shares after the transaction is completed [1][2]. Group 1: Transaction Details - The acquisition involves a dual approach of "indirect equity transfer + direct agreement transfer," where Guangzhou Pharmaceutical will acquire 100% of Guangzhou Guangyong Technology Development Co., Ltd. from Guangzhou Financial Holdings Group, indirectly controlling 233 million shares of Da An Gene [1]. - Guangzhou Pharmaceutical will also directly acquire 70.17 million shares each from Guangzhou Financial Holdings Group and Guangzhou Health Industry Investment Co., Ltd., totaling 374 million shares, which represents 26.63% of Da An Gene's total share capital [1][2]. - The total consideration for the agreement is approximately 908 million yuan, calculated at 6.47 yuan per share [2]. Group 2: Control and Governance - Despite the transfer of controlling rights, Da An Gene emphasized that there will be no change in its controlling shareholder or actual controller, with Guangzhou Guangyong Technology remaining the controlling shareholder and the actual controller being the Guangzhou Municipal People's Government [2]. - Both Guangzhou Financial Holdings Group and Guangzhou Pharmaceutical Group are enterprises controlled by the Guangzhou Municipal People's Government, indicating that this transaction is part of a strategic integration within the Guangzhou state-owned assets system [2]. Group 3: Future Steps - The signed framework agreement is a preliminary document, and formal transaction documents will be signed once the conditions outlined in the framework agreement are met [2]. - The asset evaluation report related to the equity transfer must complete the state-owned assets filing process, and the transaction is subject to operator concentration review and compliance confirmation by the Shenzhen Stock Exchange before share transfer procedures can be processed [2].